Advanced Materials,
Год журнала:
2025,
Номер
unknown
Опубликована: Май 13, 2025
Abstract
The
power
of
drugs
lies
in
their
ability
to
reach
target
sites
and
remain
place
for
a
sufficient
duration
exert
therapeutic
effects.
However,
some
drugs,
lysosomal
phagocytosis
presents
ongoing
challenges.
In
this
study,
an
engineered
o
rganelles
v
isualization
d
rug‐delivery
s
ystem
(OVDS)
is
introduced
as
subcellular
drug
visualization
redistribution
framework
that
facilitates
the
movement
molecules
from
one
organelle,
specifically
lysosomes,
another,
such
mitochondria.
As
proof‐of‐concept
OVDS
developed
facilitate
translocation
10‐hydroxycamptothecin
(HCPT)
lysosomes
This
modification
HCPT
distribution
allows
evasion
lysosome‐mediated
resistance
cancer
cells.
Unlike
traditional
chemotherapeutic
approaches,
when
incorporated
into
(HCPT‐OVDS),
positive
charge
protonation,
thereby
enabling
escape
enter
Using
HCPT‐OVDS,
substantial
accumulation
achieved
at
HCPT‐resistant
cells,
with
up
70
±
6%
efficient
translocalization
12.8
fold
enhancement
cytotoxicity.
Overall,
HCPT‐OVDS
represents
innovative
engineering
spatial
offers
promising
solution
addressing
resistance.
Journal of Medicinal Chemistry,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 22, 2025
Drug
discovery
campaigns
often
face
biopharmaceutical
challenges,
some
of
which
can
be
solved
by
a
prodrug
approach.
Prodrugs
are
enzymatically
or
chemically
transformed
in
vivo
to
produce
active
drugs.
Among
these,
medoxomil
promoieties
have
been
judiciously
employed
multiple
drug
campaigns,
leading
three
prodrugs
gaining
FDA
approval:
azilsartan
(6),
olmesartan
(20),
and
ceftobiprole
medocaril
(29),
one
approval
Japan:
prulifloxacin
(35).
The
promoiety
easily
appended
mask
carboxylic
acids,
amines,
zwitterionic
compounds,
other
polar
groups,
imparting
lipophilicity
the
parent
compound.
has
added
advantage
rapid
complete
conversion
enzymatic
pathways
across
different
tissues.
approach
used
for
drugs
spanning
classes
improve
oral
bioavailability,
solubility,
tissue
localization,
efflux,
side
effect
profiles.
This
Perspective
analyzes
history
application
discusses
their
potential
development.
Pharmaceutics,
Год журнала:
2025,
Номер
17(5), С. 626 - 626
Опубликована: Май 8, 2025
Long-acting
injectable
(LAI)
formulations
have
revolutionized
veterinary
pharmaceuticals
by
improving
patient
compliance,
minimizing
dosage
frequency,
and
therapeutic
efficacy.
These
utilize
advanced
drug
delivery
technologies,
including
microspheres,
liposomes,
oil
solutions/suspensions,
in
situ-forming
gels,
implants
to
achieve
extended
release.
Biodegradable
polymers
such
as
poly(lactic-co-glycolic
acid)
(PLGA),
polycaprolactone
(PCL)
been
approved
the
USFDA
are
widely
employed
development
of
various
LAIs,
offering
controlled
release
side
effects.
Various
classes
medicines,
non-steroidal
anti-inflammatory
drugs
(NSAIDs),
antibiotics,
reproductive
hormones,
successfully
formulated
LAIs.
Some
remarkable
LAI
products,
ProHeart®
(moxidectin),
Excede®
(ceftiofur),
POSILACTM
(recombinant
bovine
somatotropin),
show
clinical
relevance
commercial
success.
This
review
provides
comprehensive
information
on
formulation
strategies
currently
being
used
emerging
technologies
LAIs
for
purposes.
Additionally,
challenges
characterization,
vitro
testing,
vivo
correlation
(IVIVC),
safety
concerns
regarding
biocompatibility
discussed,
along
with
prospects
next-generation
Continued
advancement
field
medicine
is
essential
animal
health.
Advanced Materials,
Год журнала:
2025,
Номер
unknown
Опубликована: Май 13, 2025
Abstract
The
power
of
drugs
lies
in
their
ability
to
reach
target
sites
and
remain
place
for
a
sufficient
duration
exert
therapeutic
effects.
However,
some
drugs,
lysosomal
phagocytosis
presents
ongoing
challenges.
In
this
study,
an
engineered
o
rganelles
v
isualization
d
rug‐delivery
s
ystem
(OVDS)
is
introduced
as
subcellular
drug
visualization
redistribution
framework
that
facilitates
the
movement
molecules
from
one
organelle,
specifically
lysosomes,
another,
such
mitochondria.
As
proof‐of‐concept
OVDS
developed
facilitate
translocation
10‐hydroxycamptothecin
(HCPT)
lysosomes
This
modification
HCPT
distribution
allows
evasion
lysosome‐mediated
resistance
cancer
cells.
Unlike
traditional
chemotherapeutic
approaches,
when
incorporated
into
(HCPT‐OVDS),
positive
charge
protonation,
thereby
enabling
escape
enter
Using
HCPT‐OVDS,
substantial
accumulation
achieved
at
HCPT‐resistant
cells,
with
up
70
±
6%
efficient
translocalization
12.8
fold
enhancement
cytotoxicity.
Overall,
HCPT‐OVDS
represents
innovative
engineering
spatial
offers
promising
solution
addressing
resistance.
